Sagent Pharmaceuticals has announced the launch of Travoprost Ophthalmic Solution, USP, marking its entry into the ophthalmic market. The product is the first ophthalmic solution in Sagent’s expanding portfolio and represents a strategic move to broaden its offerings within the U.S. pharmaceutical sector..

Sagent Pharmaceuticals 宣布推出曲伏前列素滴眼液，标志着其正式进军眼科市场。该产品是 Sagent 不断扩展的产品组合中的首款眼科溶液，也代表着其在美国制药领域拓宽产品线的战略举措。

The Schaumburg, Illinois-based company revealed this development on September 15, 2025. Travoprost Ophthalmic Solution is designed for use in managing certain eye conditions, though specific details about its indications or distribution plans were not disclosed in the announcement. This launch signals Sagent’s intent to diversify its product range as it continues to grow its presence in the pharmaceutical industry..

总部位于伊利诺伊州绍姆堡的公司于2025年9月15日公布了这一进展。曲伏前列素滴眼液旨在用于管理某些眼部疾病，但公告中并未披露其适应症或分销计划的具体细节。此次推出标志着Sagent公司意图进一步丰富其产品线，同时继续扩大其在制药行业的影响力。